RELOAD-C for Loneliness
Trial Summary
What is the purpose of this trial?
More than 60% of care partners of persons with AD/ADRD report feeling lonely. Building on the existing evidence that increasing meaning and purpose in life is a strong predictor of decreased loneliness, interventions to reduce loneliness in this population may be strengthened by incorporating concepts from Meaning-Centered Psychotherapy (MCP). Thus, the overall goal of the proposed project is to reduce loneliness in care partners of patients with AD/ADRD through increasing their sense of meaning and purpose in life using concepts from MCP, delivered via a web-based platform, RELOAD-C (REducing LOneliness in Alzeheimer's Disease-Care Partners). This will be achieved through three Specific Aims. Aim 1 consists of three phases (preparatory work, stakeholder involvement with N=15 AD/ADRD care partners, and adaptation of the existing web-based platform) to produce RELOAD-C, which centralizes: 1) 6 brief videos portraying an MCP expert delivering MCP concepts; 2) links to 7 virtual group meetings (6 weekly + 1 booster) to discuss MCP concepts (of note, the support groups utilized in this study exist only as part of this research); and 3) written content expanding on the material from the MCP videos. Aim 2 evaluates usability/acceptability of RELOAD-C (defined as a task success rate ≥ 78%, and scores ≥ 68 on the System Usability Scale) with N=20 care partners of persons with AD/ADRD. Aim 3 proposes a pilot RCT to evaluate the preliminary efficacy of the RELOAD-C components (MCP videos vs. MCP-focused group discussions) in reducing loneliness and feasibility of conducting a future, large-scale RCT. N=96 AD/ADRD care partners will be randomized to: usual care, n=32; MCP videos alone via RELOAD-C, n=32; or MCP videos + weekly groups via RELOAD-C, n=32. Care partners' outcomes will be assessed at baseline, and 6-weeks and 3-months post-baseline. The investigators expect the effect sizes will be in the moderate range (.3). Feasibility is defined as: ≥ 75% consented, ≤ 30% drop-out, and 80% engagement with intervention. Reducing loneliness among care partners is of high public health significance and incorporating MCP in loneliness interventions is highly innovative. In sum, the investigators will enroll 15 care partners during Aim 1, 20 care partners during Aim 2, and 96 care partners during Aim 3.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on psychological support rather than medication changes.
What data supports the effectiveness of the treatment RELOAD-C for reducing loneliness in Alzheimer's disease care partners?
What safety data exists for the RELOAD-C treatment for loneliness?
How is the RELOAD-C treatment for loneliness in Alzheimer's caregivers different from other treatments?
Eligibility Criteria
This trial is for adult care partners of community-dwelling persons with Alzheimer's disease or related disorders (AD/ADRD) who feel lonely, as indicated by a specific loneliness scale. Participants must not be professional caregivers but rather family members or friends, speak English, have the ability to use technology like email and internet, and their role cannot be linked to employment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preparatory Work
Modification of MCP scripts for AD/ADRD care partners and stakeholder feedback
Usability and Acceptability Testing
Testing the usability and acceptability of the RELOAD-C platform with care partners
Pilot RCT
Randomized controlled trial to evaluate the efficacy of MCP videos and group discussions
Follow-up
Participants are monitored for changes in loneliness, burden, and other outcomes
Treatment Details
Interventions
- RELOAD-C
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwell Health
Lead Sponsor
National Institute on Aging (NIA)
Collaborator